Global Cardiac Biomarkers Testing Market Size By Type (Troponin, Creatine kinase-muscle/brain (CK-MB)), By Application (Myocardial Infarction, Congestive Heart Failure), By Testing Location (Point of Care Testing, Laboratory Testing), By Geographic Scope And Forecast
Published on: 2024-08-03 | No of Pages : 320 | Industry : latest updates trending Report
Publisher : MIR | Format : PDF&Excel
Global Cardiac Biomarkers Testing Market Size By Type (Troponin, Creatine kinase-muscle/brain (CK-MB)), By Application (Myocardial Infarction, Congestive Heart Failure), By Testing Location (Point of Care Testing, Laboratory Testing), By Geographic Scope And Forecast
Cardiac Biomarkers Testing Market Size And Forecast
Cardiac Biomarkers Testing Market size was valued at USD 9.7 Billion in 2022 and is projected to reach USD 25.05 Billion by 2030, growing at a CAGR of 10.9% from 2023 to 2030.
Because of changing lifestyles, the market is likely to be driven by an expanding senior population, as well as an increase in the number of patients suffering from heart attacks and chest discomfort in the next years. In its comprehensive assessment of the market, the Global Cardiac Biomarkers Testing Market research is available. Comprehensive analysis of major segments, trends, drivers, and constraints, as well as the competition landscape and factors that are playing a significant role in the market, is provided by this study. The Global Cardiac Biomarkers Testing Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.
Global Cardiac Biomarkers Testing Market Definition
Biomarkers of the heart are protein molecules that are released into the bloodstream after a heart attack or a stressful situation involving the heart. These biomarkers have the potential to serve as a diagnostic tool for a variety of cardiovascular illnesses (CVD), including cardiac ischemia, myocardial infarction, congestive heart failure, and acute coronary syndrome (ACS) (ACS). Cardiac Biomarkers Tests enable doctors to assess a patient’s risk of developing certain conditions by analyzing certain biomarkers. These tests are carried out when a patient complains of chest discomfort. Troponin, creatine kinase-muscle/brain (CK-MB), B-type natriuretic peptide (BNP), high-sensitivity C-reactive protein (hs-CRP), and other cardiac biomarkers are among the most commonly tested for cardiovascular disease (CVD) in the United States.
A class of traceable chemicals known as cardiac biomarkers, which are protein-based molecules that are utilized as indicators of biologic status, as well as for diagnostic and prognostic reasons in the heart, are protein-based traceable substances. The prevention of cardiac illnesses through the monitoring of heart conditions by cardiac biomarker testing is a revolutionary strategy for generating quick findings that may be used for immediate diagnosis and treatment of cardiac ailments.
Cardiac biomarkers are used to stratify patients at risk for a variety of cardiovascular diseases (CVDs), including myocardial infraction, congestive heart failure, acute coronary syndrome (ACS), and others. Myocardial infraction is a type of heart attack that occurs when the heart muscle is damaged. Cardiovascular biomarkers, such as myocardial muscle creatine kinase (CK-MB), troponin I and T, myoglobin, brain natriuretic peptides (BNPs), ischemia modified albumin (IMA), and others, are commonly employed as part of an integrated diagnostic strategy for cardiovascular diseases (CVDs).